The US FDA’s frenetic pace of regulatory activity in the Obama Administration’s waning days may raise concerns that agency efforts to implement the biosimilar approval pathway could hit a lull in the coming months.
However, the 351(k) application workload currently at the agency and the pending reauthorization of the biosimilar user fee program, coupled with some key court decisions anticipated in biological patent disputes, suggests
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?